Patient Services Vendor Selection Guide
Step-by-step framework to evaluate and select patient services partners – define criteria, score vendors, run…
CertaraOctober 20, 2025
U.S. International Reference Pricing: Global Implications and Pharma Strategy
Unintended global fallout of international reference pricing: How the U.S. Most Favored Nation policy could…
CertaraOctober 6, 2025
‘Most Favored Nation’ Policy Could Have Profound Impact on Global Drug Pricing if Fully Implemented
Editor’s Note: Jiwon Oh provided research support for this article. She is a Certara Market…
CertaraMay 23, 2025
Everything you need to know about ILAP 2.0
This white paper share’s key insights on the relaunch of MHRA’s Innovative Licensing and Access…
CertaraMay 19, 2025
Joint Clinical Assessment (JCA) And Potential Consequences For The Evaluation Of Gene Therapies
In October 2019, Galderma announced that the U.S. FDA approved AKLIEF® (trifarotene) Cream, 0.005% for the…
CertaraJune 17, 2024
Accelerating a drug launch with value communication technology and an integrated workflow
With early approvals for a targeted cancer drug in Brazil and Argentina, this global pharmaceutical…
CertaraOctober 2, 2023
Using customer engagement technology to create value communication tools for ABILIFY MAINTENA® (aripiprazole)
Otsuka identified several weaknesses in their existing workflow for developing value communication tools. In particular,…
CertaraOctober 2, 2023
Using Real-World Evidence to Derive an External Control Arm for a Rare Disease Drug Trial
Our client was developing a new anti-viral drug for a rare, life-threatening viral infection that…
CertaraApril 17, 2023
Using Real World Evidence to Inform Treatment Guidelines
Real-World Evidence (RWE) has become increasingly valuable in informing the development of treatment guidelines for…
CertaraApril 5, 2023
